Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study

Reports of the prevalence of antibodies to infliximab (anti-drug antibodies, ADA) are inconsistent due in part to the various assay formats used to monitor immunogenicity in the clinic and under clinical trial settings. This study aimed to determine the frequency of ADA in patients with inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Pękala, Anna, Filip, Rafał, Aebisher, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235171/
https://www.ncbi.nlm.nih.gov/pubmed/34208676
http://dx.doi.org/10.3390/jcm10122653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235171/
https://www.ncbi.nlm.nih.gov/pubmed/34208676
http://dx.doi.org/10.3390/jcm10122653

Ejemplares similares